Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms
Author:
Affiliation:
1. Department of Haematology 4th Floor Southwark Wing Guy’s and St. Thomas’ NHS Foundation Trust London UK
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16573
Reference108 articles.
1. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
2. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
3. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
4. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
5. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Haematology in the UK: A 60‐year personal perspective;eJHaem;2021-05-18
2. Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease;Journal of Experimental & Clinical Cancer Research;2021-02-01
3. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies;Hematological Oncology;2020-09-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3